Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
aTYR PHARMA INC (LIFE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO – August 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2023 results and provided a corporate update. “Throughout the second quarter we have continued to progress and invest in our clinical development program for our lead therapeu..."
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATIONOF",
"ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan . The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation , and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and stre...",
"Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. established this Code of Business Conduct and Ethics to aid the Company’s directors, officers and employees in making ethical and legal decisions when conducting the Company’s business and performing their day-to-day duties. The Company’s Board of Directors or a committee of the Board is responsible for administering the Code. The Board has delegated day-to-day responsibility for administering and interpreting the Code to a Compliance Officer. Our General Counsel has been appointed the Company’s Compliance Officer under this Code. The Company expects its directors, officers and employees to exercise reasonable judgment when conducting the Company’s business. The Company encourages..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023. Company to host multiple presentations for efzofitimod at the upcoming American Thoracic Society 2023 International Conference. February follow-on common stock offering generated $48.1 million in net proceeds. Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments. SAN DIEGO – May 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s..."
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
03/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approximately $52.0 million in gross proceeds. Company to host conference call and webcast today, March 9th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO – March 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update. “2022 was..."
02/22/2023 SC 13G LYTTON LAURENCE W reports a 8.7% stake in aTyr Pharma, Inc.
02/14/2023 SC 13G/A Venrock Healthcare Capital Partners II, L.P. reports a 4% stake in aTyr Pharma, Inc.
02/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENT February 8, 2023 RBC CAPITAL MARKETS, LLC As Representative of the several Underwriters named in Schedule I hereto c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281",
"3545 John Hopkins Court, Suite"
02/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in ATYR PHARMA INC
02/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/06/2023 8-K Other Events  Interactive Data
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 18% stake in ATYR PHARMA, INC.
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/11/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to Restated Certificate of Incorporation of aTyr Pharma, Inc",
"ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN",
"ATYR PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN"
04/22/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "OPEN MARKET SALE AGREEMENT SM",
"3545 John Hopkins Court, Suite"
04/22/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy